CTOs on the Move

Hecker and Associates

www.hecker-associates.com

 
Hecker and Associates is a Arlington, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Chinook Therapeutics

Kidney diseases are a severe and growing problem worldwide, with a lack of effective treatments often leading to dialysis, transplantation and high costs to health care systems. In the U.S. alone, kidney diseases affect an estimated 37 million people and account for over $100 billion in annual costs.

Ionpath

Ionpath delivers high definition spatial proteomics, revolutionizing tissue imaging and analysis to accelerate discovery and improve human health. Ionpath`s MIBI™ (multiplexed ion beam imaging) Platform breaks through the limitations of traditional IHC, enabling deep understanding of the tissue microenvironment with highly multiplexed quantitative single-cell analysis.

Emalex Biosciences

Developing new treatments for rare and orphan neurological conditions.

Tolmar

TOLMAR is a northern Colorado based pharmaceutical research, development, manufacturing and commercial operations company. TOLMAR develops and manufacturers both proprietary and generic pharmaceutical products with specific focus in therapeutic areas of dental, dermatology, and oncology. TOLMAR provides our customers with a competitive and sustainable combination of product development and commercial services. Our strengths include a proven development, clinical, regulatory and manufacturing infrastructure with highly trained and experienced staff. Several of our marketed products are still in an early stage growth mode.

Dianthus Therapeutics

Dianthus is a biotechnology company dedicated to designing and delivering the next generation of best-in-class monoclonal antibodies with improved selectivity and potency. Led by a multidisciplinary team of seasoned biotech entrepreneurs and scientists, we are pioneering selective antibodies of validated and emerging complement targets to allow people with rare and severe autoimmune diseases live healthier lives to their fullest potential.